TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Purpose: of determining the role of Interactive Binocular Treatment (I-BiTTM) as a complementary method of patching in amblyopia therapy.

Materials and Methods: In this randomized clinical trial study, 50 unilateral amblyopic children (25 male/25 female) less than 10 years with either best corrected visual acuity (BCVA) ≤0.3 LogMAR (Logarithm minimum angle of resolution) in amblyopic eye or difference of VA≥2 lines between two eyes will be included. Patients will be classified in the case and control groups (25 in each), randomly. Patching will be recommended in both, cases will also received I-BiTTM. The child will be asked to play I-BiTTM games through glasses with conjugate colored filters. Patching was continued for one month more in both groups. VA and stereoacuity were measured at baseline, one month at the end of I-BiTTM treatment and one month after I-BiTTM treatment.


Options:
A: Intervention Type: DEVICE; Name: 6 hours occlusion by patching; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 12 hours occlusion by patching; Assigned to Arm(s): N/A
B: Arm Label: Recommendation of Patching; Type: ACTIVE_COMPARATOR; Interventions: Other: Patching Therapy | Arm Label: Recommendation of Patching and interactive binocular treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Patching Therapy, Device: Interactive Binocular Treatment System | Intervention Type: OTHER; Name: Patching Therapy; Assigned to Arm(s): Recommendation of Patching, Recommendation of Patching and interactive binocular treatment | Intervention Type: DEVICE; Name: Interactive Binocular Treatment System; Assigned to Arm(s): Recommendation of Patching and interactive binocular treatment
C: Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: spectacles; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atropine; Assigned to Arm(s): N/A
D: Arm Label: I-BiTTM game; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM game | Arm Label: Non-I-BiTTM game; Type: ACTIVE_COMPARATOR; Interventions: Device: Non-I-BiTTM game | Arm Label: I-BiTTM DVD; Type: EXPERIMENTAL; Interventions: Device: I-BiTTM DVD | Intervention Type: DEVICE; Name: I-BiTTM game; Assigned to Arm(s): I-BiTTM game | Intervention Type: DEVICE; Name: Non-I-BiTTM game; Assigned to Arm(s): Non-I-BiTTM game | Intervention Type: DEVICE; Name: I-BiTTM DVD; Assigned to Arm(s): I-BiTTM DVD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Herbal Galactogogues on Weight Gain of the Newborns Within the First Month of Life in Breastfeeding Mothers
Brief Summary: Herbal teas with galactogoge effects have been used extensively in recent years in order to increase the amount of breast milk in lactating mothers. We also investigated whether a sleep-induced herbal tea (Still-Tee; Mamsel®) was effective in regulating the sleep of these mothers. Plain water was used as placebo.


Options:
A: Arm Label: Women with recent GDM pregnancy; Type: N/A; Interventions: N/A
B: Arm Label: Still-Tee; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Still-Tee | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Still-Tee | Arm Label: Water; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Still-Tee; Assigned to Arm(s): Placebo, Still-Tee
C: Arm Label: study herbal tea; Type: EXPERIMENTAL; Interventions: Dietary Supplement: study herbal tea | Arm Label: herbal placebo tea; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: herbal placebo tea | Intervention Type: DIETARY_SUPPLEMENT; Name: study herbal tea; Assigned to Arm(s): study herbal tea | Intervention Type: DIETARY_SUPPLEMENT; Name: herbal placebo tea; Assigned to Arm(s): herbal placebo tea
D: Arm Label: Standard care plus metformin; Type: EXPERIMENTAL; Interventions: Behavioral: Standard care, Drug: Metformin | Arm Label: Standard Care plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Standard care, Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care plus placebo, Standard care plus metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Standard care plus metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard Care plus placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Follow-up Study on the Sustained Impact of Alive & Thrive Behavior Change Communication Interventions on Infant and Young Child Feeding Practices in Bangladesh
Brief Summary: Alive \& Thrive (A\&T) is a multi-year initiative to improve infant and young child feeding (IYCF) practices. During Phase 1 (A\&T-1, 2009-2014), funded by the Bill \& Melinda Gates Foundation, A\&T aimed to reduce undernutrition and death caused by suboptimal IYCF practices in three countries - Bangladesh, Ethiopia, and Viet Nam.

In 2014, IFPRI in collaboration with DATA conducted the endline survey in Bangladesh. The overall findings of the evaluation indicate that A\&T's work in Bangladesh is a remarkable success story of scaling up what has been challenging to date in the field of nutrition: complex, high intensity and at-scale behavior change communications interventions.

In 2016, a follow up study will be conducted to determine the sustained impacts on IYCF practices, expansion of operations and promoted practices into new areas, and diffusion of IYCF information, two years after the termination of external project support.


Options:
A: Arm Label: Family Spirit Nurture (FSN); Type: EXPERIMENTAL; Interventions: Behavioral: Family Spirit Nurture (FSN), Other: Optimized Standard Care (OSC) | Arm Label: Control Program; Type: OTHER; Interventions: Other: Injury Prevention Education (IPE), Other: Optimized Standard Care (OSC) | Intervention Type: BEHAVIORAL; Name: Family Spirit Nurture (FSN); Assigned to Arm(s): Family Spirit Nurture (FSN) | Intervention Type: OTHER; Name: Injury Prevention Education (IPE); Assigned to Arm(s): Control Program | Intervention Type: OTHER; Name: Optimized Standard Care (OSC); Assigned to Arm(s): Control Program, Family Spirit Nurture (FSN)
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention
C: Arm Label: Non-intensive group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mass media | Arm Label: Intensive group; Type: EXPERIMENTAL; Interventions: Behavioral: Interpersonal behavioral change communication, Behavioral: Mass media | Intervention Type: BEHAVIORAL; Name: Interpersonal behavioral change communication; Assigned to Arm(s): Intensive group | Intervention Type: BEHAVIORAL; Name: Mass media; Assigned to Arm(s): Intensive group, Non-intensive group
D: Arm Label: Nutrition messages; Type: EXPERIMENTAL; Interventions: Behavioral: SMS | Arm Label: General health messages; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS | Intervention Type: BEHAVIORAL; Name: SMS; Assigned to Arm(s): General health messages, Nutrition messages

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Observer Blinded Controlled Non Inferiority Trial to Evaluate the Safety and Immunogenicity of Locally Manufactured Inactivated Bivalent Whole Cell-oral Cholera Vaccine (WC-OCV) 'Cholvax' in Bangladeshi Healthy Adults and Children
Brief Summary: To evaluate and compare the safety and immunogenicity of the Cholvax with ShancholTM, Investigators will conduct a clinical trial study Bangladeshi healthy adults and children. Cholvax is locally produced orally administered whole cell inactivated bivalent cholera vaccine. Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the oral cholera vaccine, Cholvax with technological support from International Vaccine Institute (IVI). Cholvax meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation. By this transfer of technology, it expected that the vaccine will become available for use in public health programs in Bangladesh and in the future in other cholera-affected countries in Asia and Africa to control endemic cholera, as well as to help control large-scale epidemics and outbreaks.

Investigators will also evaluate and compare the safety and immunogenicity of 3 Cholvax lots (lot-to-lot consistency).


Options:
A: Arm Label: cholvax; Type: EXPERIMENTAL; Interventions: Biological: Cholvax | Arm Label: shanchol; Type: ACTIVE_COMPARATOR; Interventions: Biological: Shanchol | Intervention Type: BIOLOGICAL; Name: Cholvax; Assigned to Arm(s): cholvax | Intervention Type: BIOLOGICAL; Name: Shanchol; Assigned to Arm(s): shanchol
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: killed whole cell oral cholera vaccine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Heat Killed E. coli | Intervention Type: BIOLOGICAL; Name: killed whole cell oral cholera vaccine; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Heat Killed E. coli; Assigned to Arm(s): 2
C: Arm Label: Vaccine arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: ShanChol | Arm Label: Vaccine plus hygiene and safe water arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vaccine and behaviour | Arm Label: Non-intervention arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: ShanChol; Assigned to Arm(s): Vaccine arm | Intervention Type: BEHAVIORAL; Name: Vaccine and behaviour; Assigned to Arm(s): Vaccine plus hygiene and safe water arm
D: Arm Label: Shanchol; Type: EXPERIMENTAL; Interventions: Biological: Shanchol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Shanchol; Assigned to Arm(s): Shanchol | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: When is the Best Moment to Remove the Urinary Catheter After Laparoscopic Hysterectomy: MUCH Study.
Brief Summary: Objective: The aim of this study is to evaluate if direct removal of the urine catheter after an laparoscopic hysterectomy (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery, which is the current treatment. In addition, we want to investigate patient's experience on this subject.

Study design: Randomized Controlled trial, non-inferiority study.

Study population: Women older than 18 years old, who are a laparoscopic hysterectomy for benign indication or low-grade malignancy.

Intervention:

* Group A (treatment group): the patients in this group will have their catheter directly removed in the OR after LH.
* Group B (control group): the patients in the control group will have their catheter removed according to the regular protocol of the hospital (at least 6 hours in place).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: postoperative catheterization | Arm Label: 2.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: postoperative catheterization | Intervention Type: PROCEDURE; Name: postoperative catheterization; Assigned to Arm(s): 1, 2.
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Tamsulosin | Intervention Type: DRUG; Name: Tamsulosin; Assigned to Arm(s): 2
C: Arm Label: Group A (treatment group); Type: EXPERIMENTAL; Interventions: Device: Foley catheter | Arm Label: Group B (control group); Type: ACTIVE_COMPARATOR; Interventions: Device: Foley catheter | Intervention Type: DEVICE; Name: Foley catheter; Assigned to Arm(s): Group A (treatment group), Group B (control group)
D: Arm Label: removal of catheter; Type: OTHER; Interventions: Procedure: immediate removal of in-dwelling catheter, Procedure: 24 hours delayed removal of catheter | Intervention Type: PROCEDURE; Name: immediate removal of in-dwelling catheter; Assigned to Arm(s): removal of catheter | Intervention Type: PROCEDURE; Name: 24 hours delayed removal of catheter; Assigned to Arm(s): removal of catheter

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter RCT to Evaluate the Clinical and Cost-effectiveness of a Culturally Adapted Therapy (C-MAP) in Patients With a History of Self-harm
Brief Summary: To evaluate the clinical and cost-effectiveness of a culturally adapted therapy (C-MAP) in patients with a history of self-harm


Options:
A: Arm Label: Culturally adapted therapy (C-MAP); Type: EXPERIMENTAL; Interventions: Behavioral: Culturally adapted therapy (C-MAP) | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Culturally adapted therapy (C-MAP); Assigned to Arm(s): Culturally adapted therapy (C-MAP)
B: Arm Label: CARMS therapy + TAU; Type: EXPERIMENTAL; Interventions: Other: Cognitive AppRoaches to coMbatting Suicidality (CARMS) | Arm Label: TAU; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cognitive AppRoaches to coMbatting Suicidality (CARMS); Assigned to Arm(s): CARMS therapy + TAU
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: PS CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Problem solving cognitive behaviour therapy (PS CBT) | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Problem solving cognitive behaviour therapy (PS CBT); Assigned to Arm(s): PS CBT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter RCT to Evaluate the Clinical and Cost-effectiveness of a Culturally Adapted Therapy (C-MAP) in Patients With a History of Self-harm
Brief Summary: To evaluate the clinical and cost-effectiveness of a culturally adapted therapy (C-MAP) in patients with a history of self-harm


Options:
A: Arm Label: Culturally adapted therapy (C-MAP); Type: EXPERIMENTAL; Interventions: Behavioral: Culturally adapted therapy (C-MAP) | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Culturally adapted therapy (C-MAP); Assigned to Arm(s): Culturally adapted therapy (C-MAP)
B: Arm Label: Body Acceptance Program; Type: EXPERIMENTAL; Interventions: Behavioral: Body Acceptance Program | Arm Label: Waitlist control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Body Acceptance Program; Assigned to Arm(s): Body Acceptance Program
C: Arm Label: Relaxation group; Type: ACTIVE_COMPARATOR; Interventions: Other: Relaxation group | Arm Label: Psychoeducational group; Type: EXPERIMENTAL; Interventions: Behavioral: Interventional group : PEPSUI psychoeducational program | Intervention Type: BEHAVIORAL; Name: Interventional group : PEPSUI psychoeducational program; Assigned to Arm(s): Psychoeducational group | Intervention Type: OTHER; Name: Relaxation group; Assigned to Arm(s): Relaxation group
D: Arm Label: Interventional group; Type: EXPERIMENTAL; Interventions: Other: Usual treatment and Prevention program | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Treatment | Intervention Type: OTHER; Name: Usual treatment and Prevention program; Assigned to Arm(s): Interventional group | Intervention Type: OTHER; Name: Usual Treatment; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter RCT to Evaluate the Clinical and Cost-effectiveness of a Culturally Adapted Therapy (C-MAP) in Patients With a History of Self-harm
Brief Summary: To evaluate the clinical and cost-effectiveness of a culturally adapted therapy (C-MAP) in patients with a history of self-harm


Options:
A: Arm Label: active anodal tDCS to ventrolateral prefrontal cortex (VLPFC); Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial direct current stimulation | Arm Label: sham anodal tDCS to VLPFC; Type: SHAM_COMPARATOR; Interventions: Device: Transcranial direct current stimulation | Arm Label: Discontinued prior to randomization; Type: OTHER; Interventions: Other: No intervention | Intervention Type: DEVICE; Name: Transcranial direct current stimulation; Assigned to Arm(s): active anodal tDCS to ventrolateral prefrontal cortex (VLPFC), sham anodal tDCS to VLPFC | Intervention Type: OTHER; Name: No intervention; Assigned to Arm(s): Discontinued prior to randomization
B: Arm Label: Culturally adapted therapy (C-MAP); Type: EXPERIMENTAL; Interventions: Behavioral: Culturally adapted therapy (C-MAP) | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Culturally adapted therapy (C-MAP); Assigned to Arm(s): Culturally adapted therapy (C-MAP)
C: Arm Label: SMS; Type: EXPERIMENTAL; Interventions: Device: SMS contact with patient after discharge in intervention group | Arm Label: Without SMS; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: SMS contact with patient after discharge in intervention group; Assigned to Arm(s): SMS
D: Arm Label: MYPLAN app; Type: EXPERIMENTAL; Interventions: Other: MYPLAN-safety plan as an application for smart phones | Arm Label: Safety plan on paper; Type: ACTIVE_COMPARATOR; Interventions: Other: safety plan on paper | Intervention Type: OTHER; Name: MYPLAN-safety plan as an application for smart phones; Assigned to Arm(s): MYPLAN app | Intervention Type: OTHER; Name: safety plan on paper; Assigned to Arm(s): Safety plan on paper

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection
Brief Summary: Randomized open label clinical trial to compare the clinical and microbiological efficacy of fecal microbiota transplantation, fidaxomicin, and vancomycin for relapsing Clostridium difficile infection


Options:
A: Arm Label: FMT; Type: EXPERIMENTAL; Interventions: Other: Fecal microbiota transplantation | Arm Label: Fidaxomicin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fidaxomicin | Arm Label: Vancomycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: OTHER; Name: Fecal microbiota transplantation; Assigned to Arm(s): FMT | Intervention Type: DRUG; Name: Fidaxomicin; Assigned to Arm(s): Fidaxomicin | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): Vancomycin
B: Arm Label: Fecal Transplant; Type: EXPERIMENTAL; Interventions: Biological: Fecal Transplant | Arm Label: Oral Vancomycin Taper; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): Oral Vancomycin Taper | Intervention Type: BIOLOGICAL; Name: Fecal Transplant; Assigned to Arm(s): Fecal Transplant
C: Arm Label: Colonoscopy; Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Arm Label: Nasogastric Tube (NGT); Type: EXPERIMENTAL; Interventions: Drug: Fecal Microbiota Transplant (FMT) | Intervention Type: DRUG; Name: Fecal Microbiota Transplant (FMT); Assigned to Arm(s): Colonoscopy, Nasogastric Tube (NGT)
D: Arm Label: Fresh FMT; Type: EXPERIMENTAL; Interventions: Biological: Fresh FMT | Arm Label: Frozen-and-Thawed FMT; Type: EXPERIMENTAL; Interventions: Biological: Frozen-and-Thawed FMT | Intervention Type: BIOLOGICAL; Name: Fresh FMT; Assigned to Arm(s): Fresh FMT | Intervention Type: BIOLOGICAL; Name: Frozen-and-Thawed FMT; Assigned to Arm(s): Frozen-and-Thawed FMT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study Investigating the Use of a Therapeutic Wand in Addition to Physiotherapy for Bladder Pain Syndrome
Brief Summary: Bladder pain syndrome is a condition where pain is experienced when the bladder fills with urine and eases briefly when the bladder empties. There can also be a constant need to urgently empty the bladder.

The internal pelvic floor muscles in people with bladder pain syndrome can be tense and painful, and relaxing and stretching them may improve symptoms; reducing bladder pain, urgency and how often people have to empty their bladder.

This pelvic floor release is done by specialist physiotherapists.Therapeutic wands, such as the TheraWand®, are used routinely throughout the United Kingdom to allow people to relax and stretch their pelvic floor themselves. Using a therapeutic wand has been shown to be safe and to reduce pelvic pain, improve bladder and bowel symptoms and relax the pelvic floor muscles. However, this research was conducted mostly in men with pelvic pain.

The aim of this study is to find out if using a therapeutic wand at home as well as having a specialist physiotherapist massage the pelvic floor gives any added benefit than just having the physiotherapy treatment. The investigators hope to find out if the therapeutic wand gives women a way of managing their symptoms independently in their own homes.


Options:
A: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
B: Arm Label: Group 1: Experimental; Type: ACTIVE_COMPARATOR; Interventions: Biological: Certolizumab pegol | Arm Label: Group 2: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Group 1: Experimental | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2: Placebo Comparator
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PF-04383119 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PF-04383119; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Usual physiotherapy treatment group; Type: ACTIVE_COMPARATOR; Interventions: Other: Routine physiotherapy control | Arm Label: Therapeutic Wand group; Type: EXPERIMENTAL; Interventions: Device: Therapeutic Wand | Intervention Type: DEVICE; Name: Therapeutic Wand; Assigned to Arm(s): Therapeutic Wand group | Intervention Type: OTHER; Name: Routine physiotherapy control; Assigned to Arm(s): Usual physiotherapy treatment group

Answer: D